Stock fact sheet · data as of
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): fair value, margin of safety and Wheel Score
Financial Services · Shell Companies · United States · Speculative / Distressed
Is DMAA undervalued?
DMAA closed at 10.87 on 16 Oct 2026 against a GLS average fair value of 10.74 - 1.2% above fair value, which our screens read as "fairly priced". 2 of 5 models are above the current price. There is no discount to lean on here, so the margin of safety is not the reason to look at the stock.
There is a wide gap between EPV (3.37) and GLS Growth (18.57). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files DMAA under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for DMAA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 6.84 | -37% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 17.35 | +60% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 7.58 | -30% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 18.57 | +71% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 3.37 | -69% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.2992 | -103% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Drugs Made In America Acquisition Corp. Ordinary Shares scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 3.9/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 2.6%, ROE 2.6%, ROA 2.5% - with debt at 0.00 times equity and negative free cash flow.
Drugs Made In America Acquisition Corp. Ordinary Shares pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 10/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | 2.6% |
|---|---|---|---|
| GLS Moat | 3.9 / 10 | ROE | 2.6% |
| Debt / equity | 0.00 | ROA | 2.5% |
| Free-cash-flow yield | -0.1% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 31: No options
No options are listed on Drugs Made In America Acquisition Corp. Ordinary Shares in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 31) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 7k shares a day on a market cap of $264M, with a beta of 0.00 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 12 / 25 | -1% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 6 / 15 | moat 3.9/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 7k shares/day, $264M cap, beta 0.00 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for DMAA in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Shell Companies
The 12 companies below are the closest to Drugs Made In America Acquisition Corp. Ordinary Shares by market cap within the Shell Companies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SORN Soren Acquisition Corp. | 10.02 | 0.9169 | -993% | 6No options | $264M |
| PCAP ProCap Acquisition Corp | 10.40 | 4.16 | -150% | 13No options | $264M |
| OBA Oxley Bridge Acquisition Limited | 10.40 | 12.56 | +17% | 36No options | $263M |
| ATII Archimedes Tech SPAC Partners II Co. Ordinary Shares | 8.86 | 0.0672 | -13092% | 16No options | $262M |
| OACC Oaktree Acquisition Corp. II | 10.65 | 12.68 | +16% | 39No options | $262M |
| GIW GigCapital8 Corp. | 10.20 | 1.77 | -476% | 6No options | $262M |
| TDAC Translational Development Acquisition Corp. | 10.81 | 11.77 | +8% | 32No options | $266M |
| FACT FACT II Acquisition Corp | 10.74 | 4.17 | -158% | 21No options | $261M |
| CEPV Cantor Equity Partners V, Inc. Class A Ordinary Shares | 10.20 | 5.46 | -87% | 7No options | $261M |
| SOUL Soulpower Acquisition Corp. | 10.49 | 10.66 | +2% | 38No options | $269M |
| PMTR Perimeter Acquisition Corp. I Class A Ordinary Shares | 10.44 | 3.86 | -171% | 13No options | $259M |
| PLMK Plum Acquisition Corp. IV | 10.63 | 9,909.56 | +100% | 39No options | $258M |
⚖ Compare DMAA with 7 of them All Financial Services stocks →
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about DMAA
Is DMAA undervalued right now?
Not meaningfully: at 10.87 the stock trades within a few percent of the GLS average fair value of 10.74 (1.2% above fair value, data as of 16 Oct 2026).
What is the Wheel Score of DMAA and what does it mean?
DMAA has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for DMAA?
10.74 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Drugs Made In America Acquisition Corp. Ordinary Shares report earnings next?
No upcoming earnings date is recorded for DMAA in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does DMAA have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on DMAA, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.